Unraveling Chemotherapy Resistance: Linking Tumor Metabolism, Cachexia, and Organoid InnovationPioneering Organoid Research to Uncover Drivers of Cancer Cachexia

At the forefront of translational cancer research, our laboratory is the first to harness organoid technology to identify novel tumor-derived factors responsible for the metabolic disturbances seen in cancer cachexia. This innovative approach is transforming our understanding of how tumors impact the body beyond traditional models.

Our Unique Approach:

• Living Biobank with Comprehensive Patient Profiles: We have established a living biobank of organoids, each linked to detailed clinical and biological cachexia related data from the patients who donated tissue. This resource is freely available to the global research community, fostering collaboration and accelerating discovery.
• Beyond Skeletal Muscle: While cachexia research has historically focused on skeletal muscle wasting, our studies extend to the effects of tumor-derived factors on myosteatosis, smooth muscle and the immunometabolism of leukocytes. This broader perspective allows us to uncover new mechanisms and potential therapeutic targets.
• Driving Innovation in Cachexia Research: By applying organoid models, we can precisely investigate how different tumor factors disrupt metabolism and immune function, paving the way for more effective interventions.